Pfizer (PFE.US) Q3 profit beats expectations, non-COVID products grow 7%, raises full-year guidance

Zhitong Finance APP has learned that Pfizer (PFE.US) released its fiscal year 2026 third-quarter (ended September 27) financial results before the market opened on November 3. Adjusted diluted earnings per share for the quarter were $0.87, flat year-over-year and significantly above the market consensus estimate of $0.73; GAAP diluted earnings per share were $0.56, down 9% year-over-year. Total revenue for the quarter was $16.583 billion, essentially flat year-over-year, of which product revenue was $13.255 billion, alliance revenue was $2.851 billion (up 24%), and royalty revenue was $477 million.